Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
Purpose
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type.
Conditions
- Anal Basaloid Carcinoma
- Anal Canal Cloacogenic Carcinoma
- Anal Canal Squamous Cell Carcinoma
- Anal Margin Squamous Cell Carcinoma
- Stage I Anal Cancer AJCC v8
- Stage IIA Anal Cancer AJCC v8
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- Patient must have histologically proven T1-2N0M0 invasive anal canal or anal margin
squamous cell carcinoma with tumors measuring =< 4 cm within 4 weeks prior to
randomization. This may include tumors of non-keratinizing histology such as basaloid,
transitional cell or cloacogenic histology. Patients with T1N0M0 anal margin squamous
cell carcinoma who underwent surgical excision with negative margins are not eligible
- Patients who are human immunodeficiency virus (HIV)-negative must not have lymph nodes
that are radiographically-concerning for cancer involvement using computed tomography
(CT) and positron emission tomography (PET)/CT-based criteria. Measurable disease is
not required
- Patients who are HIV-negative and do not have lymph nodes classified as lymph
node positive, but are felt to be borderline for cancer involvement must undergo
central imaging review
- NOTE: Patients requiring central imaging review will be pre-registered to
Arm S. Upon central confirmation of no lymph node involvement, eligible
patients may proceed to randomization on Step 1
- Patients will be considered to be lymph node (LN) positive and thereby not
eligible in this study if the lymph nodes meet any of the following criteria:
- Mesorectal, presacral, internal iliac or obturator LN with:
- Short axis measuring > 5 mm based on CT / magnetic resonance imaging
(MRI) OR
- Morphologic features of irregular border or central necrosis if
assessed on MRI and LN measures > 3 mm OR
- Fludeoxyglucose F-18 (FDG) uptake > blood pool (Deauville 3-5) based on
PET/CT
- External Iliac and common Iliac:
- Short-axis measuring > 1 cm based on CT / MRI OR
- Morphologic features of irregular border or central necrosis based on
CT / MRI OR
- FDG uptake > blood pool (Deauville 3-5) based on PET/CT
- Inguinal LN (superficial and deep) meeting any of the following criteria will be
ineligible unless an FNA is performed and resulting cytology is negative.
- Morphologic features of irregular border or central necrosis based on CT /
MRI
- FDG uptake > liver (Deauville 4) based on PET/CT.
- Patients who are HIV-negative and have inguinal lymph nodes that do not meet
the above criteria must undergo fine needle aspiration and have negative
histology to be eligible.
- Patients who are HIV-positive must have
- A CD4 count >= 300
- Confirmation of no lymph node involvement by central real-time review of imaging
- NOTE: Patients will be pre-registered to Arm S. Upon central confirmation of
no lymph node involvement, eligible patients may proceed to randomization on
Step 1
- Patient must have Eastern Cooperative Oncology Group (ECOG) - American College of
Radiology Imaging Network (ACRIN) performance status of 0-2
- Patient must have no history of prior radiation or chemotherapy for this malignancy
- Patient must not have had prior potentially curative surgery (i.e. abdominal-perineal
resection) for carcinoma of the anus
- Patients with excisional biopsy procedure are eligible provided there was tumor
involvement of the anal canal and/or anal verge prior to resection
- Patient must not be receiving any other standard anti-cancer therapy or experimental
agent concurrently with the study drugs
- Patient must not have intercurrent illness including, but not limited to, ongoing or
active infection or psychiatric/social situations that, in the judgement of the
investigator, would limit compliance with study requirements
- Patient must not have had significant cardiovascular disease including myocardial
infarction, unstable angina, stroke, transient ischemic attack, symptomatic coronary
artery disease, symptomatic congestive heart failure, or uncontrolled cardiac
arrhythmia within 6 months of randomization
- Patient must not have a history of a different malignancy unless they have been
disease-free for at least 2 years and are deemed by the investigator to be at low risk
of recurrence
- Individuals with the following cancers are eligible if diagnosed and treated
within the past 5 years: cervical cancer in situ and basal cell or squamous cell
carcinoma of the skin
- Patient must not have active autoimmune or connective disease
- Patients who are on anti-coagulation with warfarin within 2 weeks prior to
registration and are considering the use of capecitabine, must use an alternative
anti-coagulant
- NOTE: Low molecular weight heparin is permitted provided the patient's
prothrombin time (PT)/international normalized ratio (INR) is < 1.5
- Patients who will receive capecitabine and are on Dilantin for a seizure disorder must
have Dilantin levels checked weekly
- Hemoglobin > 10 g/dL (within 2 weeks prior to registration)
- Platelets >= 100,000/mm^3 (within 2 weeks prior to registration)
- Absolute neutrophil count >= 1500/mm^3 (within 2 weeks prior to registration)
- Serum creatinine must be < 1.5 X upper limit of normal (ULN), or calculated creatinine
clearance must be > 60 ml/min (within 2 weeks prior to registration)
- Total bilirubin must be < 2 X ULN (within 2 weeks prior to registration)
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 X institutional
ULN (within 2 weeks prior to registration)
- Albumin >= 3.0 g/dL (within 2 weeks prior to registration)
- Women must not be pregnant or breast-feeding because the study treatment administered
may cause harm to an unborn fetus or breastfeeding child. All females of childbearing
potential must have a blood test or urine study within 2 weeks prior to registration
to rule out pregnancy. A female of childbearing potential is any woman, regardless of
sexual orientation or whether they have undergone tubal ligation, who meets the
following criteria: 1) has achieved menarche at some point, 2) has not undergone a
hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal
(amenorrhea following cancer therapy does not rule out childbearing potential) for at
least 24 consecutive months (i.e., has had menses at any time in the preceding 24
consecutive months)
- Women of childbearing potential and sexually active males must be strongly advised to
use accepted and effective method(s) of contraception or to abstain from sexual
intercourse for the duration of their participation in the study and for at least 6
months after the completion of treatment
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Active Comparator Arm A (standard-dose chemoradiation) |
Patients undergo 28 fractions of intensity-modulated radiation therapy (IMRT). Within 24 hours, patients also receive mitomycin IV over 30 minutes or less on day 1 and either fluorouracil IV over 24 hours on days 1-4 and 29-32 or capecitabine PO BID 5 days per week (Monday - Friday) until completion of IMRT in the absence of disease progression or unacceptable toxicity. |
|
|
Experimental Arm B (de-intensified chemoradiation) |
Patients undergo 20 or 23 fractions of IMRT. Within 24 hours, patients also receive mitomycin IV over 30 minutes or less on day 1 and either fluorouracil IV over 24 hours on days 1-4 or capecitabine PO BID 5 days per week (Monday - Friday) until completion of IMRT in the absence of disease progression or unacceptable toxicity. |
|
Recruiting Locations
Anchorage, Alaska 98508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Fairbanks, Alaska 99701
Kingman, Arizona 86401
Phoenix, Arizona 85004
Fort Smith, Arkansas 72903
Site Public Contact
800-378-9373
Arroyo Grande, California 93420
Burbank, California 91505
Carmichael, California 95608
Carmichael, California 95608
Elk Grove, California 95758
Orange, California 92868
Rocklin, California 95765
Sacramento, California 95816
San Luis Obispo, California 93401
Santa Maria, California 93444
Woodland, California 95695
Aurora, Colorado 80012
Aurora, Colorado 80045
Site Public Contact
720-848-0650
Boulder, Colorado 80304
Colorado Springs, Colorado 80907
Colorado Springs, Colorado 80907
Colorado Springs, Colorado 80909
Site Public Contact
719-365-2406
Colorado Springs, Colorado 80920
Site Public Contact
719-364-6700
Colorado Springs, Colorado 80923
Denver, Colorado 80210
Denver, Colorado 80218
Englewood, Colorado 80113
Englewood, Colorado 80113
Englewood, Colorado 80113
Fort Collins, Colorado 80524
Site Public Contact
970-297-6150
Fort Collins, Colorado 80528
Greeley, Colorado 80631
Lakewood, Colorado 80228
Littleton, Colorado 80120
Littleton, Colorado 80122
Longmont, Colorado 80501
Loveland, Colorado 80538
Site Public Contact
970-203-7083
Parker, Colorado 80138
Pueblo, Colorado 81004
Thornton, Colorado 80260
Frankford, Delaware 19945
Lewes, Delaware 19958
Newark, Delaware 19713
Newark, Delaware 19713
Newark, Delaware 19713
Newark, Delaware 19718
Rehoboth Beach, Delaware 19971
Washington, District of Columbia 20010
Site Public Contact
202-877-8839
Aventura, Florida 33180
Site Public Contact
954-461-2180
Coral Gables, Florida 33146
Site Public Contact
305-243-2647
Deerfield Beach, Florida 33442
Site Public Contact
305-243-2647
Miami, Florida 33136
Site Public Contact
305-243-2647
Miami, Florida 33176
Site Public Contact
786-596-2000
Orlando, Florida 32806
Plantation, Florida 33324
Site Public Contact
305-243-2647
Weston, Florida 33331
Boise, Idaho 83706
Boise, Idaho 83712
Caldwell, Idaho 83605
Coeur d'Alene, Idaho 83814
Fruitland, Idaho 83619
Meridian, Idaho 83642
Meridian, Idaho 83642
Nampa, Idaho 83686
Nampa, Idaho 83687
Post Falls, Idaho 83854
Twin Falls, Idaho 83301
Aurora, Illinois 60504
Bloomington, Illinois 61704
Canton, Illinois 61520
Carbondale, Illinois 62902
Carterville, Illinois 62918
Carthage, Illinois 62321
Centralia, Illinois 62801
Chicago, Illinois 60611
Chicago, Illinois 60612
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Danville, Illinois 61832
Decatur, Illinois 62526
Decatur, Illinois 62526
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Effingham, Illinois 62401
Effingham, Illinois 62401
Eureka, Illinois 61530
Galesburg, Illinois 61401
Galesburg, Illinois 61401
Site Public Contact
309-344-2831
Kewanee, Illinois 61443
Macomb, Illinois 61455
Mattoon, Illinois 61938
Maywood, Illinois 60153
Site Public Contact
708-226-4357
Mount Vernon, Illinois 62864
Site Public Contact
618-242-4600
O'Fallon, Illinois 62269
Ottawa, Illinois 61350
Pekin, Illinois 61554
Pekin, Illinois 61554
Peoria, Illinois 61615
Peoria, Illinois 61615
Peoria, Illinois 61636
Peoria, Illinois 61637
Peru, Illinois 61354
Peru, Illinois 61354
Site Public Contact
815-664-4141
Princeton, Illinois 61356
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Urbana, Illinois 61801
Urbana, Illinois 61801
Washington, Illinois 61571
Richmond, Indiana 47374
Ames, Iowa 50010
Site Public Contact
515-956-4132
Ames, Iowa 50010
Carroll, Iowa 51401
Cedar Rapids, Iowa 52402
Site Public Contact
319-297-2900
Cedar Rapids, Iowa 52402
Clive, Iowa 50325
Site Public Contact
515-241-3305
Clive, Iowa 50325
Council Bluffs, Iowa 51502
Council Bluffs, Iowa 51503
Site Public Contact
712-322-4136
Creston, Iowa 50801
Des Moines, Iowa 50309
Site Public Contact
515-241-6727
Des Moines, Iowa 50309
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-282-2200
Des Moines, Iowa 50314
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Des Moines, Iowa 50316
Site Public Contact
515-241-8704
West Des Moines, Iowa 50266-7700
Site Public Contact
515-343-1000
West Des Moines, Iowa 50266
Fairway, Kansas 66205
Garden City, Kansas 67846
Great Bend, Kansas 67530
Kansas City, Kansas 66160
Lawrence, Kansas 66044
Olathe, Kansas 66061
Overland Park, Kansas 66210
Pittsburg, Kansas 66762
Salina, Kansas 67401
Topeka, Kansas 66606
Site Public Contact
785-295-8000
Westwood, Kansas 66205
Lexington, Kentucky 40504
Lexington, Kentucky 40504
Lexington, Kentucky 40509
New Orleans, Louisiana 70121
Bath, Maine 04530
Biddeford, Maine 04005
Damariscotta, Maine 04543
Portland, Maine 04102
Site Public Contact
207-885-7565
Rockport, Maine 04856
Sanford, Maine 04073
Site Public Contact
207-459-1600
Sanford, Maine 04073
Scarborough, Maine 04074
South Portland, Maine 04106
Baltimore, Maryland 21204
Site Public Contact
443-849-3706
Boston, Massachusetts 02118
Site Public Contact
617-638-8265
Boston, Massachusetts 02215
Site Public Contact
617-667-9925
Ann Arbor, Michigan 48109
Site Public Contact
800-865-1125
Battle Creek, Michigan 49017
Bay City, Michigan 48706
Brighton, Michigan 48116
Site Public Contact
800-865-1125
Clarkston, Michigan 48346
Detroit, Michigan 48201
Farmington Hills, Michigan 48334
Flint, Michigan 48532
Flint, Michigan 48532
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49048
Lansing, Michigan 48910
Lansing, Michigan 48912
Lapeer, Michigan 48446
Mount Clemens, Michigan 48043
Muskegon, Michigan 49444
Niles, Michigan 49120
Site Public Contact
616-391-1230
Norton Shores, Michigan 49444
Novi, Michigan 48374
Petoskey, Michigan 49770
Port Huron, Michigan 48060
Reed City, Michigan 49677
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
Southfield, Michigan 48075
Traverse City, Michigan 49684
Wyoming, Michigan 49519
Bemidji, Minnesota 56601
Brainerd, Minnesota 56401
Burnsville, Minnesota 55337
Burnsville, Minnesota 55337
Coon Rapids, Minnesota 55433
Deer River, Minnesota 56636
Detroit Lakes, Minnesota 56501
Duluth, Minnesota 55805
Duluth, Minnesota 55805
Duluth, Minnesota 55805
Edina, Minnesota 55435
Fosston, Minnesota 56542
Fridley, Minnesota 55432
Hibbing, Minnesota 55746
Site Public Contact
218-786-3308
Maple Grove, Minnesota 55369
Maplewood, Minnesota 55109
Maplewood, Minnesota 55109
Minneapolis, Minnesota 55407
Minneapolis, Minnesota 55415
Minneapolis, Minnesota 55454
Monticello, Minnesota 55362
Park Rapids, Minnesota 56470
Robbinsdale, Minnesota 55422
Saint Louis Park, Minnesota 55416
Saint Paul, Minnesota 55101
Saint Paul, Minnesota 55102
Sandstone, Minnesota 55072
Shakopee, Minnesota 55379
Stillwater, Minnesota 55082
Virginia, Minnesota 55792
Waconia, Minnesota 55387
Willmar, Minnesota 56201
Woodbury, Minnesota 55125
Bolivar, Missouri 65613
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
Site Public Contact
573-651-5550
Creve Coeur, Missouri 63141
Farmington, Missouri 63640
Site Public Contact
314-996-5569
Jefferson City, Missouri 65109
Joplin, Missouri 64804
Joplin, Missouri 64804
Kansas City, Missouri 64154
Lee's Summit, Missouri 64064
North Kansas City, Missouri 64116
Rolla, Missouri 65401
Rolla, Missouri 65401
Site Public Contact
573-458-6379
Saint Joseph, Missouri 64506
Saint Louis, Missouri 63110
Saint Louis, Missouri 63129
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Saint Louis, Missouri 63141
Site Public Contact
314-251-7066
Saint Peters, Missouri 63376
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
Springfield, Missouri 65804
Site Public Contact
417-269-4520
Springfield, Missouri 65807
Site Public Contact
417-269-4520
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Sunset Hills, Missouri 63127
Site Public Contact
314-996-5569
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Great Falls, Montana 59405
Kalispell, Montana 59901
Missoula, Montana 59802
Missoula, Montana 59804
Kearney, Nebraska 68847
Omaha, Nebraska 68114
Site Public Contact
402-334-4773
Omaha, Nebraska 68114
Site Public Contact
402-354-5144
Omaha, Nebraska 68114
Omaha, Nebraska 68122
Omaha, Nebraska 68124
Omaha, Nebraska 68130
Omaha, Nebraska 68131
Henderson, Nevada 89052
Henderson, Nevada 89052
Las Vegas, Nevada 89102
Las Vegas, Nevada 89106
Las Vegas, Nevada 89109
Las Vegas, Nevada 89119
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89135
Las Vegas, Nevada 89144
Las Vegas, Nevada 89144
Las Vegas, Nevada 89148
Las Vegas, Nevada 89148
Las Vegas, Nevada 89169
Reno, Nevada 89502
Reno, Nevada 89503
Reno, Nevada 89509
Lebanon, New Hampshire 03756
Basking Ridge, New Jersey 07920
Site Public Contact
212-639-7592
Camden, New Jersey 08103
Site Public Contact
856-325-6757
Long Branch, New Jersey 07740
Middletown, New Jersey 07748
Site Public Contact
212-639-7592
Montvale, New Jersey 07645
Site Public Contact
212-639-7592
New Brunswick, New Jersey 08903
Site Public Contact
732-235-7356
Toms River, New Jersey 08755
Voorhees, New Jersey 08043
Site Public Contact
856-325-6757
Albuquerque, New Mexico 87102
Albuquerque, New Mexico 87102
Albuquerque, New Mexico 87109
Albuquerque, New Mexico 87109
Bronx, New York 10461
Bronx, New York 10461
Bronx, New York 10467
Canandaigua, New York 14424
Site Public Contact
585-396-6161
Commack, New York 11725
Site Public Contact
212-639-7592
Cooperstown, New York 13326
Dansville, New York 14437
Harrison, New York 10604
Site Public Contact
212-639-7592
Lake Success, New York 11042
Site Public Contact
516-734-8896
Mount Kisco, New York 10549
New York, New York 10003
New York, New York 10011
New York, New York 10029
New York, New York 10032
New York, New York 10065
Site Public Contact
212-639-7592
Rochester, New York 14606
Site Public Contact
585-758-7877
Rochester, New York 14620
Site Public Contact
585-341-8113
Rochester, New York 14642
Site Public Contact
585-275-5830
Uniondale, New York 11553
Site Public Contact
212-639-7592
Webster, New York 14580
Bismarck, North Dakota 58501
Fargo, North Dakota 58103
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Jamestown, North Dakota 58401
Beachwood, Ohio 44122
Beavercreek, Ohio 45431
Boardman, Ohio 44512
Centerville, Ohio 45459
Centerville, Ohio 45459
Chardon, Ohio 44024
Cincinnati, Ohio 45219
Cincinnati, Ohio 45220
Cincinnati, Ohio 45236
Cincinnati, Ohio 45242
Cleveland, Ohio 44106
Cleveland, Ohio 44109
Cleveland, Ohio 44111
Cleveland, Ohio 44195
Columbus, Ohio 43210
Dayton, Ohio 45409
Dayton, Ohio 45415
Dayton, Ohio 45415
Findlay, Ohio 45840
Findlay, Ohio 45840
Findlay, Ohio 45840
Franklin, Ohio 45005-1066
Franklin, Ohio 45005
Greenville, Ohio 45331
Greenville, Ohio 45331
Independence, Ohio 44131
Kettering, Ohio 45409
Kettering, Ohio 45429
Mayfield Heights, Ohio 44124
Mentor, Ohio 44060
Middleburg Heights, Ohio 44130
Parma, Ohio 44129
Ravenna, Ohio 44266
Sandusky, Ohio 44870
Troy, Ohio 45373
Troy, Ohio 45373
Warren, Ohio 44484
West Chester, Ohio 45069
Westlake, Ohio 44145
Westlake, Ohio 44145
Youngstown, Ohio 44501
Oklahoma City, Oklahoma 73120
Site Public Contact
405-752-3402
Bend, Oregon 97701
Clackamas, Oregon 97015
Clackamas, Oregon 97015
Coos Bay, Oregon 97420
Newberg, Oregon 97132
Portland, Oregon 97213
Portland, Oregon 97225
Portland, Oregon 97239
Beaver, Pennsylvania 15009
Carlisle, Pennsylvania 17015
Chadds Ford, Pennsylvania 19317
Danville, Pennsylvania 17822
Erie, Pennsylvania 16505
Farrell, Pennsylvania 16121
Greensburg, Pennsylvania 15601
Site Public Contact
724-838-1900
Harrisburg, Pennsylvania 17109
Johnstown, Pennsylvania 15901
Site Public Contact
814-534-4724
Lewisburg, Pennsylvania 17837
Lewistown, Pennsylvania 17044
Mechanicsburg, Pennsylvania 17050
Monroeville, Pennsylvania 15146
Moon, Pennsylvania 15108
Philadelphia, Pennsylvania 19111
Site Public Contact
215-728-4790
Pittsburgh, Pennsylvania 15213
Site Public Contact
412-647-2811
Pittsburgh, Pennsylvania 15215
Site Public Contact
412-784-4900
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-621-2334
Pittsburgh, Pennsylvania 15237
Site Public Contact
412-367-6454
Pittsburgh, Pennsylvania 15243
Site Public Contact
412-502-3920
Pottsville, Pennsylvania 17901
Seneca, Pennsylvania 16346
Site Public Contact
814-676-7900
Uniontown, Pennsylvania 15401
Site Public Contact
724-437-2503
Washington, Pennsylvania 15301
West Reading, Pennsylvania 19611
Site Public Contact
610-988-9323
Wilkes-Barre, Pennsylvania 18711
Williamsport, Pennsylvania 17701
Site Public Contact
800-598-4282
Williamsport, Pennsylvania 17754
York, Pennsylvania 17408
Site Public Contact
717-724-6760
Anderson, South Carolina 29621
Gaffney, South Carolina 29341
Greer, South Carolina 29651
Spartanburg, South Carolina 29303
Union, South Carolina 29379
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57117-5134
Nashville, Tennessee 37232
Site Public Contact
800-811-8480
Conroe, Texas 77384
Dallas, Texas 75235
Dallas, Texas 75390
Houston, Texas 77030
Houston, Texas 77079
League City, Texas 77573
Sugar Land, Texas 77478
Farmington, Utah 84025
Salt Lake City, Utah 84106
Salt Lake City, Utah 84112
Berlin, Vermont 05602
Site Public Contact
802-225-5400
Burlington, Vermont 05401
Burlington, Vermont 05405
Saint Johnsbury, Vermont 05819
Aberdeen, Washington 98520
Bellingham, Washington 98225
Site Public Contact
360-788-8223
Bremerton, Washington 98310
Centralia, Washington 98531
Edmonds, Washington 98026
Everett, Washington 98201
Issaquah, Washington 98029
Lacey, Washington 98503
Longview, Washington 98632
Renton, Washington 98055
Seattle, Washington 98107
Seattle, Washington 98122
Sedro-Woolley, Washington 98284
Vancouver, Washington 98664
Walla Walla, Washington 99362
Yakima, Washington 98902
Appleton, Wisconsin 54911
Ashland, Wisconsin 54806
Ashland, Wisconsin 54806
Burlington, Wisconsin 53105
Eau Claire, Wisconsin 54701
Germantown, Wisconsin 53022
Grafton, Wisconsin 53024
Green Bay, Wisconsin 54311
Hayward, Wisconsin 54843
Johnson Creek, Wisconsin 53038
Kenosha, Wisconsin 53142
La Crosse, Wisconsin 54601
Madison, Wisconsin 53792
Site Public Contact
800-622-8922
Marinette, Wisconsin 54143
Marshfield, Wisconsin 54449
Milwaukee, Wisconsin 53209
Milwaukee, Wisconsin 53215
Milwaukee, Wisconsin 53233
Minocqua, Wisconsin 54548
Mukwonago, Wisconsin 53149
New Richmond, Wisconsin 54017
Oconomowoc, Wisconsin 53066
Site Public Contact
262-928-7878
Oshkosh, Wisconsin 54904
Racine, Wisconsin 53406
Rice Lake, Wisconsin 54868
Sheboygan, Wisconsin 53081
Spooner, Wisconsin 54801
Stevens Point, Wisconsin 54482
Summit, Wisconsin 53066
Superior, Wisconsin 54880
Site Public Contact
701-364-6272
Two Rivers, Wisconsin 54241
Waukesha, Wisconsin 53188
Wauwatosa, Wisconsin 53226
West Allis, Wisconsin 53227
Weston, Wisconsin 54476
Weston, Wisconsin 54476
Sheridan, Wyoming 82801
More Details
- NCT ID
- NCT04166318
- Status
- Recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
Detailed Description
PRIMARY OBJECTIVES: I. To determine whether de-intensified chemoradiation for early stage squamous cell carcinoma of the anal canal (SCCA) is able to maintain excellent 2-year disease control of 85% or higher while improving anorectal health-related quality of life (HRQL), compared to standard-dose chemoradiation therapy (CRT), as measured by the change in the Fecal Incontinence Quality of Life scale (FIQoL) instrument coping/behavior domain from baseline to 1 year. SECONDARY OBJECTIVES: I. To compare changes in patient-reported outcomes (as per Fecal Incontinence Severity Index [FISI], Patient Reported Outcomes Measurement Information System [PROMIS], International Index of Erectile Function [IIEF], Sexual Function-Vaginal Changes Questionnaire [SVQ], and Vaginal Assessment Scale [VAS]/Vulvar Assessment Scale [VuAS] instruments) between the experimental and control arm. II. To compare patterns of failure (local and regional relapse versus distant; in-field versus out-of-field of radiation), disease control, and overall survival between experimental and control arm. III. To correlate vaginal dilator use during radiation delivery with sexual function. IV. To measure changes in serum total testosterone from baseline to up to 12 months after radiation. V. To validate the utility of image features of inguinal and pelvic lymph nodes obtained prior to treatment as a prognostic indicator that can identify patients with early-stage anal squamous cell carcinoma for whom treatment with de-intensified chemoradiation is appropriate. VI. To determine whether an online, interactive educational tool (eContour) may improve the quality of radiation target delineation for anal cancer. VII. To determine the incidence of and predictors for cardiovascular toxicity in patients receiving fluorouracil (5-FU) or capecitabine. OUTLINE: Patients are randomized to 1 of 2 arms. ARM A (STANDARD-DOSE CHEMORADIATION): Patients undergo 28 fractions of intensity-modulated radiation therapy (IMRT). Within 24 hours, patients also receive mitomycin intravenously (IV) over 30 minutes or less on day 1 and either fluorouracil IV over 24 hours on days 1-4 and 29-32 or capecitabine orally (PO) twice daily (BID) 5 days per week (Monday - Friday) until completion of IMRT in the absence of disease progression or unacceptable toxicity. ARM B (DE-INTENSIFIED CHEMORADIATION): Patients undergo 20 or 23 fractions of IMRT. Within 24 hours, patients also receive mitomycin IV over 30 minutes or less on day 1 and either fluorouracil IV over 24 hours on days 1-4 or capecitabine PO BID 5 days per week (Monday - Friday) until completion of IMRT in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 6 weeks, every 3 months for years 1-2, every 6 months for year 3, then annually for years 4-5.